Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110110 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110110 33017904!7361049!33017904     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 143 (ä): 110110 Nephropedia Template TP {{tp|p=33017904|t=2020. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19 |pdf=|usr=}}{{33017904}} gab.com Text Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33017904 #FOAvip Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19. Twit Text FOAVip Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33017904 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33017904 #FOAvip English Wikipedia <ref>{{Cite pmid|33017904}}</ref> Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19 #MMPMID33017904 Kavanagh O; Marie Healy A; Dayton F; Robinson S; O'Reilly NJ; Mahoney B; Arthur A; Walker G; Farragher JP Med Hypotheses 2020[Oct]; 143 (ä): 110110 PMID33017904show ga Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19. |Administration, Inhalation[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Asthma/drug therapy[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials, Phase I as Topic[MESH] |Clinical Trials, Phase II as Topic[MESH] |Coronavirus Infections/*drug therapy[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/*administration & dosage[MESH] |Lung/*drug effects[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Patient Safety[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH] |Treatment Outcome[MESH]Inhaled hydroxychloroquine to improve efficacy and reduce harm in the (epmc).pdf DeepDyve Pubget Overpricing